Category Archives: Novel therapeutics

Therapy for EBV-associated Lymphomas

A virus-targeted therapy for
Epstein Barr virus associated lymphomas  

Phoenicia is working to bring an innovative therapeutic approach for deadly EBV-associated lymphomas into clinical trials with a new generation and oral virus-targeted therapeutic.

Epstein Barr virusPhoenicia Founder Douglas V. Faller developed a method to activate silent genes within the dormant EBV virus, which resides in lymphoma cells.

The EBV virus, whether a “passenger” or the cancer-causing agent, can then serve as a target for therapeutics. Activating the viral TK gene causes activation of a common antiviral pro-drug, selectiving killing the lymphoma cells containing the virus.  Continue reading

Refractory Wound Therapeutic NIH Grant

NIH grant to convert a potent IV
therapy for refractory wounds into
a topical formulation

Phoenicia has received a new small business grant from the National Institutes of Health for studies to convert an intravenous therapy which healed refractory, disabling leg ulcers in hemolytic anemias, sickle cell disease and β-thalassemia, into a topical preparation which can be used readily by patients world-wide. Continue reading